Efectos beneficiosos no anticonceptivos de la píldora anticonceptiva

Jordan, 1961, Pulmonary embolism, Lancet, ii, 1146, 10.1016/S0140-6736(61)91061-3 Martínez Salmeán, 2008, Historia de la anticoncepción hormonal en España, 3 Skouby, 2004, Contraceptive use and behaviour in the 21st century: a comprehensive study across five European countries, Eur J Contracept Reprod Health Care, 9, 57, 10.1080/13625180410001715681 http://www.equipodaphne.es/archivos/encuestas/ (ultimo acceso el 16/12/08). Dawood, 2006, Primary dysmenorrhoea: advances in pathogenesis and management, Obstet Gynecol, 108, 428, 10.1097/01.AOG.0000230214.26638.0c Proctor, 2001, Combined oral contraceptive pill as treatment for primary dysmenorrhoea, Cochrane Database of Systematic Reviews Davis, 2005, Oral contraceptives for dysmenorrhoea in adolescents girls: a randomized trial, Obstet Gynecol, 106, 97, 10.1097/01.AOG.0000165826.03915.65 Oehler, 2003, Menorrhagia: an update, Acta Obstet Gybnecol Scand, 82, 405, 10.1034/j.1600-0412.2003.00097.x 1998, Effects of contraceptives on haemoglobin and ferritin, Contraception, 58, 262 Iyer, 2000, Oral contraceptive pills for heavy menstrual bleeding, Cochrane Database of Systematic Reviews Fraser, 1991, Randomized trial of 2 hormonal and 2 prostaglandin inhibition agents in women with a complaint of menorrhagia, Aust Nz J Obstet Gynecol, 31, 66, 10.1111/j.1479-828X.1991.tb02769.x 2005, Non contraceptive health benefits of combined oral contraception, Hum Reprod Update, 11, 513, 10.1093/humupd/dmi019 Wittchen, 2002, Prevalence, incidence and stability of premenstrual dysphoric disorder in the community, Psychol Med, 32, 119, 10.1017/S0033291701004925 Douglas, 2002, Premenstrual syndrome. Evidence-based treatment in family practice, Can Fam Physician, 48, 1789 Freeman, 2001, Evaluation of a unique oral contraceptive in the treatment of premenstrual dysphoric disorder, J Women Health & Gender Based Medicine, 10, 561, 10.1089/15246090152543148 Pearlstein, 2005, Treatment of premenstrual dysphoric disorder with a new drospirenone containing oral contraceptive formulation, Contraception, 72, 414, 10.1016/j.contraception.2005.08.021 Yonkers, 2005, Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder, Obstet Gynecol, 106, 492, 10.1097/01.AOG.0000175834.77215.2e Schaffir, 2006, Hormonal contraception and sexual desire: a critical review, J Sex Marital Ther, 32, 305, 10.1080/00926230600666311 Henry-Suchet, 1997, Hormonal contraception and pelvis inflammatory disease, Eur J Contracept Reprod Health Care, 2, 263, 10.3109/13625189709165305 Burkman, 2004, Safety concerns and health benefits associated with oral contraception, Am J Obstet Gynecol, 190, S5, 10.1016/j.ajog.2004.01.061 Shaw, 2002, Acne: effect of hormones on pathogenesis and management, Am J Clin Dermatol, 3, 571, 10.2165/00128071-200203080-00007 Arowojolu AO, Gallo MF, López LM, Grimes DA, Garner SE. Píldoras anticonceptivas orales para el tratamiento del acné (revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008 Número 1. Oxford: Update Software Ltd. Disponible en: http://w.w.w.update-software.com (Traducida de The Cochrane Library, 2008 Issue 1. Chichester,UK: John Wiley & Sons.Ltd.). Thorneycroft, 2004, Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment, Cutis, 74, 123 Maloney, 2007, Drospirenone 3 mg/ethinylestradiol 20 μg combined oral contraceptive in the treatment of acne vulgaris, Obstet Gynecol, 109, 11S Koltun, 2008, Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial, Contraception, 77, 249, 10.1016/j.contraception.2007.11.003 Recker, 1992, Bone gain in young adult women, JAMA, 268, 2403, 10.1001/jama.1992.03490170075028 World Health Organization. Research on the menopause. WHO Tech Rep Ser n.° 866. Geneva: 1996. Kuohung, 2000, Low-dose oral contraceptives and bone mineral density: an evidence-based analysis, Contraception, 61, 77, 10.1016/S0010-7824(00)00086-X López LM, Grimes DA, Schulz KF, Curtis KM. Anticonceptivos con esteroides: efecto sobre las fracturas óseas en mujeres. (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2007 número 4. Oxford:Update Software Ltd. Disponible en: http://www.update- software.com. 1987, The reduction in risk of ovarian cancer associated with oral contraceptive use, N Engl J Med, 316, 650, 10.1056/NEJM198703123161102 Vessey, 1995, Endometrial and ovarian cancer and oral contraceptives. Findings in a large cohort study, Br J Cancer, 71, 1340, 10.1038/bjc.1995.260 La Veccia, 2006, Oral contraceptives and ovarian cancer: an update, 1998-2004, Eur J Cancer Prev, 15, 117, 10.1097/01.cej.0000179274.24200.9d Whittemore, 2004, Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations, Br J Cancer, 91, 1911, 10.1038/sj.bjc.6602239 2008, Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23.257 women with ovarian cancer and 87.303 controls, Lancet, 371, 303, 10.1016/S0140-6736(08)60167-1 Schlesselman, 1997, Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner's guide to meta-analysis, Hum Reprod, 12, 1851, 10.1093/humrep/12.9.1851 1999 Fernández, 2001, Oral contraceptives and colorectal cancer risk: a meta-analysis, Br J Cancer, 84, 722, 10.1054/bjoc.2000.1622